# **Brefeldin A**

#### **GEF** inhibitor

Inhibitor of intracellular protein transport and protein secretion, interfering with trafficking in the *trans*-Golgi network, leading to the accumulation of cycling proteins in ERGIC clusters. Blocks ADP-ribosylation factor (Arf) in an inactive GDP-bound conformation and thereby prevents binding of COPI coats to ERGIC and Golgi membranes. Upon brefeldin A treatment the Golgi rapidly tubulates and fuses with the ER by an energy-, temperature-, and microtubule-dependent process. In contrast, the drug has little effect on the ERGIC, which keeps its identity, although the ERGIC clusters become larger and more uniformly distributed in the cytoplasm of the cells. Inhibits intracellular collagen degradation. Also inhibits apical Na<sup>+</sup> channels in epithelia. Induces apoptosis.

Citations: 39

View Online »


## **Ordering Information**

**Order Online** »

BML-G405-0005	5mg
BML-G405-0025	25mg
BML-G405-0100	100mg

Manuals, SDS & CofA

**View Online »** 



### **Handling & Storage**

**Use/Stability** As indicated on product label or CoA when stored as recommended.

Long Term Storage -20°C

**Shipping** Ambient Temperature

### Regulatory Status RUO - Research Use Only

#### **Product Details**

Alternative Name BFA, Ascotoxin, Decumbin

**Appearance** White to off-white solid.

**CAS** 20350-15-6

Couple Target GEF

Couple Type Inhibitor

Formula  $C_{16}H_{24}O_4$ 

MI 14: 1369

**MW** 280.4

Purity ≥98% (HPLC)

**Solubility** Soluble in DMSO (20mg/ml), 100% ethanol (5mg/ml),

methanol, acetone or ethyl acetate (1mg/ml).

Source Isolated from Eupenicillium brefeldianum.

Last modified: May 29, 2024

